Based on the concept that neuroendocrine tumors widely express somatostatin receptors and as recommended by Food and Drug Administration and reported in literature (35, 36), we treated our patient with lanreotide acetate, a synthetic cyclical octapeptide analog of somatostatin to inhibit VIP release and improve the WDHA syndrome. The gene discussed is SST; the disease is neuroendocrine neoplasm.